News

A Slight Chemical Alteration Makes a TB Drug More Effective

Tuberculosis continues to become more resistant to existing drug regimens resulting in a need for constant innovation on the part of drug researchers. In an article published by Medicalxpress.com which can be found here, researchers are reported to have found a chemical alteration that makes fluoroquinolones, an existing group of TB-fighting drugs, more effective against drug resistant TB. The article provides an in-depth characterization of the TB enzymes targeted by fluoroquinolones and the mutations that cause resistance. The researchers discovered that by creating a critical change in the chemical composition of moxifloxacin, a broad-spectrum fluoroquinolone antibacterial, they were able to overcome the resistance caused by these mutated enzymes. This could mean more effective treatment for TB patients.

More News
29 Nov 2018
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
2 Oct 2018
The first ever U.N. General Assembly’s high-level meeting (UNHLM) on tuberculosis took place on Wednesday, September 26 in New York City. The U.N. delegation of countries agreed to ambitious targets including a commitment to finding 40 million undiagnosed cases of TB by the end of 2022 and...
18 Sep 2018
In an article written by Lucica Ditiu, Executive Director, Stop TB Partnership, and Jacqueline Huh, Head, Strategic Initiatives & Innovative Financing, Stop TB, the 'valleys of death' that hold back TB new tools innovation are discussed. These two valleys occur between new tool development and...